ReviewPathologie (Heidelberg, Germany)2026
[TNM classification of melanoma : Evolution and limitations].
Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of melanoma is increasing, accounting for the majority of deaths related to skin cancer. The TNM classification has served as the foundation for staging and treatment decisions for decades.
objectivesThis review critically analyzes the historical development of the TNM classification of melanoma and systematically outlines its limitations in the context of current molecular pathological findings. MATERIALS AND
methodsA narrative literature review was conducted considering AJCC editions 1-8 and current studies on prognostic biomarkers, gene expression profiles, and circulating tumor DNA.
resultsThe TNM classification shows significant limitations: some stage III patients have a more favorable prognosis than stage II patients, biologically distinct melanoma subtypes are not adequately considered, and immunological parameters and mitotic rate are absent from the current edition. Gene expression profiling and circulating tumor DNA analyses enable more precise risk stratification than purely clinicopathological parameters.
conclusionsIntegration of molecular and immunological biomarkers into future classification systems is necessary to enable individualized therapeutic decision-making.
Indexed as
Identifiers
42684448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.